Fluoroquinolones vs β-Lactams for Empirical Treatment of Immunocompetent Patients With Skin and Soft Tissue Infections: A Meta-analysis of Randomized Controlled Trials

OBJECTIVE To compare the effectiveness and safety of fluoroquinolones with β-lactams in the treatment of patients with skin and soft tissue infections (SSTIs). METHODS We searched the PubMed database, Cochrane Database of Controlled Trials, and references of relevant articles for study reports published between January 1980 and February 2006. RESULTS Twenty randomized controlled trials that enrolled 4817 patients were included in the analysis. Fluoroquinolones as empirical treatment of patients with SSTIs were more effective than β-lactams for the clinically evaluable patients (90.4% vs 88.2%; odds ratio [OR], 1.29; 95% confidence interval [CI], 1.00-1.66). This was also true in subset analyses of randomized controlled trials that studied ciprofloxacin (OR, 2.49; 95% CI, 1.45-4.26) and for patients with mild to moderate infections (OR, 1.83; 95% CI, 1.13-2.96). In contrast, no difference was found between the compared regimens for patients with moderate to severe infections (OR, 1.12; 95% CI, 0.80-1.55), for patients who did not receive third-generation cephalosporins as the comparator antibiotic (OR, 0.99; 95% CI, 0.73-1.34), or for the microbiologically evaluable patients (OR, 1.19; 95% CI, 0.89-1.59). Fluoroquinolones were also associated with more adverse effects (19.2% vs 15.2%; OR, 1.33; 95% CI, 1.13-1.57). CONCLUSION The high proportion of successfully treated patients in the compared groups of antibiotics and the development of more adverse effects associated with fluoroquinolone use suggest that these antibiotics do not have substantial advantages compared with β-lactams for empirical treatment of patients with SSTIs.

[1]  James X. Song,et al.  Sequential intravenous/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infection. , 2005, International journal of antimicrobial agents.

[2]  D. Nicolau,et al.  Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. , 2005, Surgical infections.

[3]  M. Jacobs,et al.  Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. , 2005, Current opinion in microbiology.

[4]  B. Bozdoğan,et al.  Antistaphylococcal Activity of DX-619, a New Des-F(6)-Quinolone, Compared to Those of Other Agents , 2005, Antimicrobial Agents and Chemotherapy.

[5]  Spencer E. Harpe,et al.  Pseudomonas aeruginosa, Staphylococcus aureus, and Fluoroquinolone Use , 2005, Emerging infectious diseases.

[6]  A. Wanger,et al.  Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002. , 2004, International journal of antimicrobial agents.

[7]  K. Tomecki,et al.  Antibiotics: what's new? , 2004, Cutis (New York, N.Y.).

[8]  D. Elston Epidemiology and prevention of skin and soft tissue infections. , 2004, Cutis.

[9]  W. Joseph Staphylococcal resistance and oral cephalosporins for skin and skin structure infections. , 2004, Cutis (New York, N.Y.).

[10]  S. Ibbotson,et al.  A randomized controlled trial (volunteer study) of sitafloxacin, enoxacin, levofloxacin and sparfloxacin phototoxicity , 2003, The British journal of dermatology.

[11]  Jerome J. Schentag,et al.  Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. , 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  H. Eichler,et al.  Target Site Concentrations of Ciprofloxacin after Single Intravenous and Oral Doses , 2002, Antimicrobial Agents and Chemotherapy.

[13]  E. Miller The penicillins: a review and update. , 2002, Journal of midwifery & women's health.

[14]  D. Talan,et al.  Once-daily, high-dose levofloxacin versus ticarcillin-clavulanate alone or followed by amoxicillin-clavulanate for complicated skin and skin-structure infections: a randomized, open-label trial. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[15]  B. Miskin,et al.  Once-Daily Oral Gatifloxacin versus Oral Levofloxacin in Treatment of Uncomplicated Skin and Soft Tissue Infections: Double-Blind, Multicenter, Randomized Study , 2001, Antimicrobial Agents and Chemotherapy.

[16]  R. Ramphal,et al.  Randomized, double-blind, multicenter trial comparing clinafloxacin with imipenem as empirical monotherapy for febrile granulocytopenic patients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  N. Christou,et al.  Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections , 2001, Antimicrobial Agents and Chemotherapy.

[18]  B. Miskin,et al.  MOXIFLOXACIN VERSUS CEPHALEXIN IN THE TREATMENT OF UNCOMPLICATED SKIN INFECTIONS , 2000, International journal of clinical practice.

[19]  H. Al-Ajmi,et al.  A comparison of the photosensitizing potential of trovafloxacin with that of other quinolones in healthy subjects. , 2000, The Journal of antimicrobial chemotherapy.

[20]  A. Petrilli,et al.  Oral ciprofloxacin vs. intravenous ceftriaxone administered in an outpatient setting for fever and neutropenia in low-risk pediatric oncology patients: randomized prospective trial. , 2000, Medical and pediatric oncology.

[21]  Justin J. Richards,et al.  Evaluation of Phototoxic Potential of Gemifloxacin in Healthy Volunteers Compared with Ciprofloxacin , 1999, Chemotherapy.

[22]  A. Vibhagool,et al.  Pharmacokinetics of levofloxacin in healthy Thai male volunteers. , 1999, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[23]  J. Verhoef,et al.  Frequency of Occurrence and Antimicrobial Susceptibility of Bacterial Pathogens Associated with Skin and Soft Tissue Infections During 1997 from an International Surveillance Programme , 1999, European Journal of Clinical Microbiology and Infectious Diseases.

[24]  Benjamin A Lipsky,et al.  Sparfloxacin versus ciprofloxacin for the treatment of community-acquired, complicated skin and skin-structure infections. , 1999, Clinical therapeutics.

[25]  J. Ramirez,et al.  Intravenous and oral mono- or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. , 1999, The Journal of antimicrobial chemotherapy.

[26]  C. Meyerhoff,et al.  Safety, tolerability and pharmacokinetics of the new long-acting quinolone DW-116 after single and multiple dosing in healthy subjects. , 1998, The Journal of antimicrobial chemotherapy.

[27]  W. Neto,et al.  A MULTICENTRE, DOUBLE‐BLIND, RANDOMISED STUDY COMPARING THE EFFICACY AND SAFETY OF ORAL LEVOFLOXACIN VERSUS CIPROFLOXACIN IN THE TREATMENT OF UNCOMPLICATED SKIN AND SKIN STRUCTURE INFECTIONS , 1998, International journal of clinical practice.

[28]  Lewis Rt,et al.  Soft Tissue Infections , 1998, World Journal of Surgery.

[29]  R. Dawe,et al.  Phototoxicity in quinolones: comparison of ciprofloxacin and grepafloxacin. , 1997, The Journal of antimicrobial chemotherapy.

[30]  Jeffrey W. Smith,et al.  Multicenter, Randomized Study Comparing Levofloxacin and Ciprofloxacin for Uncomplicated Skin and Skin Structure Infections , 1997, Southern medical journal.

[31]  D. Partsch,et al.  Cost-Effectiveness Comparison of Sequential Ofloxacin versus Standard Switch Therapy , 1997, The Annals of pharmacotherapy.

[32]  M. Drehobl,et al.  Fleroxacin 400 mg once daily versus ofloxacin 400 mg twice daily in skin and soft tissue infections. , 1997, Chemotherapy.

[33]  Benjamin A Lipsky,et al.  Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  A. Jadad,et al.  The importance of quality of primary studies in producing unbiased systematic reviews. , 1996, Archives of internal medicine.

[35]  A R Jadad,et al.  Assessing the Quality of Randomized Controlled Trials: Current Issues and Future Directions , 1996, International Journal of Technology Assessment in Health Care.

[36]  R. Stern,et al.  Photoreactions with a fluoroquinolone antimicrobial: Evening versus morning dosing , 1994, Clinical pharmacology and therapeutics.

[37]  Denilson Barbosa,et al.  Effect of sodium fusidate and ofloxacin on Staphylococcus aureus colonization and infection in patients on continuous ambulatory peritoneal dialysis. , 1994, Clinical nephrology.

[38]  R. Powers Open trial of oral fleroxacin versus amoxicillin/clavulanate in the treatment of infections of skin and soft tissue. , 1993, The American journal of medicine.

[39]  R. Nichols,et al.  Comparison of oral fleroxacin with oral amoxicillin/clavulanate for treatment of skin and soft tissue infections. , 1993, The American journal of medicine.

[40]  H. Tassler Comparative efficacy and safety of oral fleroxacin and amoxicillin/clavulanate potassium in skin and soft tissue infections. , 1993, The American journal of medicine.

[41]  L. Parish,et al.  Systemic antimicrobial therapy for skin and skin structure infections: comparison of fleroxacin and ceftazidime. , 1993, American Journal of Medicine.

[42]  J. Tooth,et al.  A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. , 1992, The Journal of antimicrobial chemotherapy.

[43]  J. Lentino,et al.  Intravenous fleroxacin versus ceftazidime for lower respiratory tract and skin and soft-tissue infections. , 1992, Clinical Therapeutics.

[44]  Benjamin A Lipsky,et al.  OFLOXACIN VERSUS CEPHALEXIN FOR TREATING SKIN AND SOFT TISSUE INFECTIONS , 1992, International journal of dermatology.

[45]  T. Lubowski,et al.  Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study , 1992, Antimicrobial Agents and Chemotherapy.

[46]  K. Neldner Double-blind randomized study of oral temafloxacin and cefadroxil in patients with mild to moderately severe bacterial skin infections. , 1991, The American journal of medicine.

[47]  L. Parish,et al.  Systemic antimicrobial therapy in skin and skin structure infections: comparison of temafloxacin and ciprofloxacin. , 1991, The American journal of medicine.

[48]  R. Powers,et al.  Ofloxacin versus cephalexin in the treatment of skin, skin structure, and soft-tissue infections in adults. , 1991, Clinical Therapeutics.

[49]  Jerome J. Schentag,et al.  Clinical and economic evaluation of oral ciprofloxacin after an abbreviated course of intravenous antibiotics. , 1991, The American journal of medicine.

[50]  R. Powers Soft Tissue Infections in the Emergency Department: The Case for the Use of ‘Simple’ Antibiotics , 1991, Southern medical journal.

[51]  J. Plouffe,et al.  Intravenous/oral ciprofloxacin versus ceftazidime in the treatment of serious infections. , 1989, The American journal of medicine.

[52]  L. Gentry,et al.  Intravenous/oral ciprofloxacin versus intravenous ceftazidime in the treatment of serious gram-negative infections of the skin and skin structure. , 1989, The American journal of medicine.

[53]  L. Dominguez,et al.  Brief report: Prospective, controlled, randomized, non-blind comparison of intravenous/oral ciprofloxacin with intravenous ceftazidime in the treatment of severe surgical infections , 1989 .

[54]  R. O. Brennan,et al.  Comparison of the safety and efficacy of intravenous ciprofloxacin and intravenous ceftazidime in the treatment of selected infections. , 1989, The American journal of medicine.

[55]  C. A. Ramirez,et al.  Intravenous ciprofloxacin or ceftazidime in selected infections. A prospective, randomized, controlled study. , 1989, The American journal of medicine.

[56]  E. Rodriguez-Noriega,et al.  Efficacy and safety of intravenous ciprofloxacin in the treatment of serious infections. A comparison with ceftazidime. , 1989, The American journal of medicine.

[57]  L. Gentry,et al.  Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections. A multicenter trial. , 1989, Archives of internal medicine.

[58]  C. Santini,et al.  Alterations of coagulase-negative staphylococcal flora in cardiac surgery patients: comparative study between cefamandole and pefloxacin perioperative prophylaxis. , 1989, Journal of chemotherapy.

[59]  P. Colletti,et al.  Pulmonary Kaposi's sarcoma: clinical findings and results of therapy. , 1989, The American journal of medicine.

[60]  L. Parish,et al.  Systemic treatment of cutaneous infections. A comparative study of ciprofloxacin and cefotaxime. , 1987, The American journal of medicine.

[61]  C. Ramírez-Ronda,et al.  Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. , 1987, The American journal of medicine.

[62]  A. Bisno Cutaneous infections: microbiologic and epidemiologic considerations. , 1984, The American journal of medicine.

[63]  S. Dogra,et al.  A Guide to Selection and Appropriate Use of Macrolides in Skin Infections , 2003, American journal of clinical dermatology.

[64]  J. Mand'ák,et al.  Changes of the serum antibiotic levels during open heart surgery (ceftazidim, ciprofloxacin, clindamycin). , 2000, Acta medica.

[65]  M. Kinzig,et al.  Pharmacokinetics and tissue penetration of piperacillin/tazobactam with particular reference to its potential in abdominal and soft tissue infections. , 1994, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[66]  L. Gentry Therapy with newer oral beta-lactam and quinolone agents for infections of the skin and skin structures: a review. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[67]  L. Nicolle,et al.  Ofloxacin use in a geriatric population. , 1991, Chemotherapy.

[68]  S. Singletary,et al.  The oncologic risks of skin preservation at mastectomy when combined with immediate reconstruction of the breast. , 1991, Surgery, gynecology & obstetrics.

[69]  J. Tooth,et al.  High dose intravenous ciprofloxacin in febrile neutropenic patients. , 1990, The Journal of antimicrobial chemotherapy.

[70]  R. Walstad,et al.  Pharmacokinetics and tissue penetration of Timentin: a simultaneous study of serum, urine, lymph, suction blister and subcutaneous thread fluid. , 1986, The Journal of antimicrobial chemotherapy.